Maze Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Maze Therapeutics reported Q2 2026 net loss of $44.7M ($0.76/share) on higher R&D expenses ($34.9M) and G&A costs ($13.1M) as it advances MZE829 (Phase 2 HORIZON trial for AMKD) and MZE782 (Phase 2 CIPheR trial for PKU initiated, Phase 2 CKD trial planned H1 2027). Cash position strengthened to $494.9M as of June 30, 2026 (from $360.0M at Dec 31, 2025) following an April 2026 equity offering of ~$150M gross proceeds; company expects cash runway into 2029. Licensed $20M milestone from Shionogi for MZE001 in Q1 2026.
Why this rating
Clinical-stage pipeline progress on track (routine); strong cash position ($495M = 112% of market cap) extends runway; modest 4.5% Q2 net loss vs. 2.4% in same quarter YoY—expenses rising with trial progression, expected for clinical company.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.